Nilstat

Pruritus Vulvae, Trichomonas Vaginitis, Pruritus Ani + 13 more

Treatment

16 Active Studies for Nilstat

What is Nilstat

Nystatin

The Generic name of this drug

Treatment Summary

Nystatin is a medication used to treat fungal infections caused by yeast and certain types of fungi. It is produced by a strain of bacteria called Streptomyces noursei and is similar to Amphotericin B. Nystatin is most effective when applied directly to the infected area, as it does not get absorbed by the body when taken orally or topically. It is primarily used to treat skin, mucous membrane, and gastrointestinal fungal infections.

Nystatin

is the brand name

image of different drug pills on a surface

Nilstat Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nystatin

Nystatin

1979

252

Effectiveness

How Nilstat Affects Patients

Nystatin is an antifungal medication used to treat fungal infections caused by certain types of yeast. It works by breaking down the cell wall of the yeast, preventing it from growing. It has limited effectiveness against other types of organisms, including bacteria, protozoa, and viruses. It is not suitable for use in the body, so it is only used to treat external and gastrointestinal infections. Resistance to nystatin is rare in _Candida albicans_ but more common in other species of _Candida_.

How Nilstat works in the body

Nystatin works by creating a hole or pore in the cell membrane of fungi. This pore changes the membrane's permeability, which causes the cell's contents to leak out and disrupts the proper functioning of the cell. Nystatin is a selective drug because it binds to an ingredient in fungal cell walls, which is different than the ingredient in mammal cell walls.

When to interrupt dosage

The prescribed dose of Nilstat is contingent upon the diagnosed state, such as cutaneous candidiasis, Skin candida and corticosteroid-responsive dermatoses. The amount also changes according to the mode of delivery (e.g. Insert or Insert - Vaginal) outlined in the following table.

Condition

Dosage

Administration

Skin candida

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Anal candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Skin Diseases

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Oral

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Low; Birthweight

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Ani

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

cutaneous candidiasis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Urinary Tract Infection (UTI)

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candida albicans

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Pruritus Vulvae

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Trichomonas Vaginitis

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Invasive

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Candidiasis, Vulvovaginal

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Yeast Infection

100000.0 [USP'U]/mL, , 100.0 [USP'U]/mg, 100.0 units/mg, 100.0 mg/mg, 500000.0 [USP'U], 10000.0 [USP'U]/mL, 500000.0 [USP'U]/mL, 100000.0 units, 500000.0 units, 100000.0 units/mL, 1000000.0 units, 200000.0 units, 100000.0 [USP'U], 100000.0 [iU]/mL, 6.75 mg/mL, 6.0 mg/mg, 1.2 mg/mg, 25.0 units/mg

Oral, Suspension, Suspension - Oral, , Ointment, Topical, Ointment - Topical, Cream, Cream - Topical, Powder, Powder - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, film coated, Tablet, film coated - Oral, Kit, Kit - Oral, Solution / drops, Suppository - Vaginal, Vaginal, Suppository, Cream - Vaginal, Solution / drops - Oral, Liquid, Liquid - Oral, Tablet - Vaginal, Tablet, Tablet - Oral, Kit - Topical, Capsule - Oral, Capsule, Lozenge - Oral, Lozenge, Insert - Vaginal, Insert, Powder, for suspension, Powder, for suspension - Oral, Solution - Oral, Solution, Cream - Oral, Oral; Topical, Cream - Oral; Topical

Warnings

Nilstat has one contraindication, hence it should not be taken when encountering any of the conditions noted in the below table.

Nilstat Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nystatin may interact with Pulse Frequency

There are 20 known major drug interactions with Nilstat.

Common Nilstat Drug Interactions

Drug Name

Risk Level

Description

Revefenacin

Major

Nystatin may decrease the excretion rate of Revefenacin which could result in a higher serum level.

Ambrisentan

Minor

The excretion of Ambrisentan can be decreased when combined with Nystatin.

Asunaprevir

Minor

The excretion of Asunaprevir can be decreased when combined with Nystatin.

Atorvastatin

Minor

The excretion of Atorvastatin can be decreased when combined with Nystatin.

Atrasentan

Minor

The excretion of Atrasentan can be decreased when combined with Nystatin.

Nilstat Toxicity & Overdose Risk

The lowest toxic dose of nystatin in rats found to be 10 g/kg. Taking a large dose of nystatin (more than 5 million units per day) may cause nausea and gastrointestinal distress, but there have been no reports of serious harm.

Nilstat Novel Uses: Which Conditions Have a Clinical Trial Featuring Nilstat?

39 active trials are currently underway to assess the potential of Nilstat in the management of Urinary Tract Infection (UTI), Yeast Infection and Pruritus Ani.

Condition

Clinical Trials

Trial Phases

Pruritus Ani

0 Actively Recruiting

Candida albicans

0 Actively Recruiting

Skin candida

0 Actively Recruiting

Anal candidiasis

0 Actively Recruiting

Candidiasis, Invasive

4 Actively Recruiting

Phase 3, Not Applicable

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Candidiasis, Oral

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Low; Birthweight

2 Actively Recruiting

Not Applicable

Skin Diseases

0 Actively Recruiting

cutaneous candidiasis

0 Actively Recruiting

Candidiasis

0 Actively Recruiting

Candidiasis, Vulvovaginal

2 Actively Recruiting

Not Applicable, Phase 3

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Pruritus Vulvae

0 Actively Recruiting

Candidiasis, Vulvovaginal

0 Actively Recruiting

Nilstat Reviews: What are patients saying about Nilstat?

4

Patient Review

4/21/2014

Nilstat for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

This treatment is effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nilstat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How quickly does NILSTAT work?

"You will take the nystatin liquid four times a day, after meals and before bedtime. It is important not to eat or drink for thirty minutes after taking the liquid. Two days is usually when the nystatin starts working. Even after your condition improves, you will need to continue taking or using nystatin for an additional two days."

Answered by AI

How long do you use NILSTAT for?

"If you're using NILSTAT and don't see improvement within two weeks, or if symptoms return shortly after stopping treatment, you should contact your doctor."

Answered by AI

Can you get NILSTAT over the counter?

"You must speak to a pharmacist before using this product."

Answered by AI

What is NILSTAT used for?

"NILSTAT is a medication used to treat intestinal candidiasis, also known as thrush. This is an infection in your gut caused by the Candida fungus. NILSTAT is classified as an antifungal agent, meaning it works by damaging the cell wall of the Candida fungus, causing it to die."

Answered by AI

Clinical Trials for Nilstat

Image of Direct Helpers in Hialeah, United States.

Rifaximin + ORT for Diarrhea

6 - 12
All Sexes
Hialeah, FL

The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are: How does rifaximin 200 mg move through and leave the body in children with acute diarrhea? Is rifaximin safe for children in this age group? Does rifaximin plus ORT help resolve diarrhea faster than ORT alone? Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes. Participants will: Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone Receive oral rehydration therapy according to the investigator's standard of care Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only) Provide stool samples to identify bacterial pathogens Keep a diary of stool frequency and consistency to help determine when diarrhea resolves Be monitored for side effects, vital signs, and laboratory changes

Phase 4
Recruiting

Direct Helpers (+4 Sites)

Bausch Health Americas, Inc.

Have you considered Nilstat clinical trials?

We made a collection of clinical trials featuring Nilstat, we think they might fit your search criteria.
Go to Trials
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA

This is a Phase 4, interventional, multi-center pharmacokinetics (PK) study in up to 200 adult patients who are residing in an ICU. This will compare the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the PK profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE), and iohexol in critically ill patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We further hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. Firstly, population PK (PopPK) modeling will be used to develop meropenem and cefepime PopPK models informed by CysC, CysC-based eGFR equations, SCR, and SCREs (renal function biomarkers), and iohexol clearance. Secondly, model diagnostics will then be used to compare the predictive performances of the renal function biomarkers PopPK models for each antibiotic relative to iohexol PopPK model. Lastly, Monte Carlo simulation (MCS) will be used to design PK/ pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker PopPK model with the best predictive performance for use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.

Phase 4
Recruiting

Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)

Have you considered Nilstat clinical trials?

We made a collection of clinical trials featuring Nilstat, we think they might fit your search criteria.
Go to Trials
Image of Children's Hospital of Philadelphia in Philadelphia, United States.

Antifungal Therapy Duration for Candidemia in Children

120 - 18
All Sexes
Philadelphia, PA

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

Recruiting
Has No Placebo

Children's Hospital of Philadelphia (+21 Sites)

Brian Fisher, DO

Image of Rush University Medical Center in Chicago, United States.

Menstrual Cups for Vaginal Infections

15 - 35
Female
Chicago, IL

HIV remains a global pandemic with 37 million infected. In western Kenya, 16% of women in the general population and 29% of the poorest women have HIV. The HIV and sexually transmitted infection (STI) epidemics overlap with broader reproductive health concerns. Menstrual hygiene management is a big problem in low- and middle-income countries and a lack of menstrual products negatively impacts women's work-life. This comes from cultural taboos, stigma, and discrimination, promoting secrecy around menstruation, high cost of menstrual products, use of traditional materials (e.g. rags, cotton wool, etc.) causing leakage and odor, and lack of water and safe hygiene facilities. Menstrual cups designed for use during sex may help women prevent Bacterial vaginosis (BV) and STIs through hygienic period practices, and may help them avoid bad practices in an attempt to maintain vaginal dryness. The goal of this interventional trial is to test the impact of menstrual cups on vaginal microbiome, BV, and STIs of poor women at high risk for STIs and HIV. We predict to see 25% less BV, our primary outcome, over one year. This trial aims to learn more about the safety of the intervention, and understand what is needed to fully implement the program.

Phase 2
Waitlist Available

Rush University Medical Center

Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Data Accountability + Doula Support for Maternal Health Disparities

12 - 99
Female
Chapel Hill, NC

This project-also known as "Accountability for Care through Undoing Racism \& Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase social support. ACURE4Moms is a pragmatic 4-arm cluster randomized controlled trial conducted with 39 prenatal practices across North Carolina. Practices have been randomly assigned to receive either: Arm 1 (Standard Care): North Carolina Medicaid Care management for high-risk pregnancies; Arm 2 (Data Accountability and Transparency): North Carolina Medicaid Care Management + Practice-level Data Accountability interventions; Arm 3 (Community-Based Doula Support): North Carolina Medicaid Care Management + Community-Based Doula support intervention for high-risk patients during pregnancy and postpartum; or Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): North Carolina Medicaid Care Management + Both Arms 2 and 3 interventions. During each practice's 2-year intervention period, the practice will initiate prenatal care for \~750-1,500 patients (up to 60,000 patients total), whose outcomes the investigators will follow and compare between arms until all these patients have reached 1-year post-delivery.

Recruiting
Has No Placebo

University of North Carolina at Chapel Hill

Jennifer H Tang, MD, MSCR

Have you considered Nilstat clinical trials?

We made a collection of clinical trials featuring Nilstat, we think they might fit your search criteria.
Go to Trials